Back

Parkinson’s disease phenotypes in patient specific brain organoids are improved by HP-β-CD treatment

Barmpa, K.; Rosety, I.; Smits, L. M.; Arias-Fuenzalida, J.; Walter, J.; Gomez-Giro, G.; Monzel, A. S.; Qing, X.; Cruciani, G.; Boussaad, I.; Jaeger, C.; Rakovic, A.; Berger, E.; Antony, P.; Klein, C.; Krüger, R.; Seibler, P.; Jarazo, J.; Schwamborn, J. C.; Bolognin, S.

2019-10-22 neuroscience
10.1101/813089 bioRxiv
Show abstract

The etiology of Parkinsons disease (PD) is only partially understood despite the fact that environmental causes, risk factors, and specific gene mutations are contributors to the disease. Biallelic mutations in the PTEN-induced putative kinase 1 (PINK1) gene involved in mitochondrial homeostasis, vesicle trafficking, and autophagy, are sufficient to cause PD. By comparing PD patient-derived cells, we show differences in their energetic profile, imbalanced proliferation, apoptosis, mitophagy, and a reduced differentiation efficiency to dopaminergic neurons compared to control cells. Using CRISPR/Cas9 gene editing, correction of a patients point mutation ameliorated the metabolic properties and neuronal firing rates but without reversing the differentiation phenotype. However, treatment with 2-Hydroxypropyl-{beta}-Cyclodextrin (HP-{beta}-CD) increased the mitophagy capacity of neurons leading to an improved dopaminergic differentiation of patient specific neurons in midbrain organoids. In conclusion, we show that treatment with a repurposed compound is sufficient for restoring dopaminergic differentiation of PD patient-derived cells.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.